Multiple Myeloma Clinical Trial
Official title:
A Phase 3b, Multicenter, Open-label, Daratumumab Long-term Extension Study
The purpose of this study is to provide ongoing access to study treatments for participants with multiple myeloma or smoldering multiple myeloma benefiting from treatment in certain Janssen Research and Development (R&D) studies that use daratumumab as part of the study treatment regimen: access for all participants regardless of treatment group in daratumumab studies and access to participants in daratumumab-containing arms in the non-daratumumab studies will be allowed from studies which have reached clinical cutoff for final analysis. Certain long-term safety data will continue to be collected from study participants.
| Status | Recruiting |
| Enrollment | 500 |
| Est. completion date | April 30, 2026 |
| Est. primary completion date | January 30, 2026 |
| Accepts healthy volunteers | No |
| Gender | All |
| Age group | N/A and older |
| Eligibility | Inclusion Criteria: - Participants must be actively receiving daratumumab (either as monotherapy or in combination with other study treatment) in certain Janssen research and development (R&D) studies or receiving other study treatment in a Janssen R&D daratumumab study for participants with multiple myeloma or smoldering multiple myeloma which has reached clinical cutoff for final analysis continue to benefit from study treatment, not have experienced disease progression or unmanageable toxicity while receiving daratumumab, not have met the withdrawal criteria set forth in the parent study, and have had the last dose of study treatment within the previous 3 months - Investigator's assessment that the benefit of continued study treatment will outweigh the risks - A female participant of childbearing potential must have a negative pregnancy test at screening and must agree to further serum or urine pregnancy tests during the study - A male participant must agree not to donate sperm for the purpose of reproduction during the study and for a minimum of 3 months after receiving the last dose of study treatment - Must sign an informed consent form (ICF; or their legally acceptable representative must sign) indicating that the participant understands the purpose of, and procedures required for, the study and is willing to participate in the study - Willing and able to adhere to the lifestyle restrictions specified in this protocol Exclusion Criteria: - Has taken any disallowed therapies or treatment for the disease under study between the completion of the parent study and the planned first dose of study treatment - Any condition for which, in the opinion of the investigator, participation would not be in the best interest of the participant (for example, compromise the well-being) or that could prevent, limit, or confound the protocol-specified assessments - Known allergies, hypersensitivity, or intolerance to study treatments or their excipients (refer to the daratumumab investigator brochure (IB) and local country prescribing information for dexamethasone, carfilzomib, pomalidomide, and lenalidomide) - Vaccinated with an investigational vaccine (except for Coronavirus disease [COVID-19])or live attenuated or replicating viral vector vaccines within 4 weeks prior to enrollment |
| Country | Name | City | State |
|---|---|---|---|
| Belgium | ZNA Stuivenberg | Antwerpen | |
| China | Beijing Chaoyang Hospital | Beijing | |
| China | The First Bethune Hospital of Jilin University | Changchun | |
| China | Fujian Medical University | Fuzhou | |
| China | Guangdong General Hospital | Guangzhou | |
| China | Nanfang Hospital | Guangzhou | |
| China | First Affiliated Hospital Medical School of Zhejiang University | Hangzhou | |
| China | First affiliated Hospital of Zhejiang University | Hangzhou | |
| China | Ruijin Hospital Shanghai Jiao Tong University | Shanghai | |
| China | Shanghai Changzheng Hospital | Shanghai | |
| China | First Affiliated Hospital SooChow University | Suzhou | |
| China | Henan Cancer Hospital | Zhengzhou | |
| Denmark | Aarhus University Hospital | Aarhus N | |
| France | Centre Hospitalier Universitaire (CHU) de Caen | Caen | |
| France | CHU Nantes | Nantes Cedex 1 | |
| France | Hopital Saint Louis | Paris | |
| France | Hopital Haut Leveque | Pessac | |
| Germany | Klinikum Chemnitz gGmbH | Chemnitz | |
| Germany | Asklepios Klinik Altona | Hamburg | |
| Germany | Universitaetsklinikum Tuebingen der Eberhard-Karls-Universitaet, Abteilung fuer Innere Medizin II, | Tübingen | |
| Greece | Alexandra General Hospital of Athens | Athens Attica | |
| Korea, Republic of | Pusan National University Hospital | Busan | |
| Korea, Republic of | National Cancer Center | Goyang-si | |
| Korea, Republic of | Chonnam National University Hwasun Hospital | Hwasun | |
| Korea, Republic of | Seoul National University Bundang Hospital | Seongnam | |
| Korea, Republic of | Samsung Medical Center | Seoul | |
| Korea, Republic of | Seoul National University Hospital | Seoul | |
| Korea, Republic of | The Catholic University of Korea Seoul St. Mary's Hospital | Seoul | |
| Poland | Wojewodzki Szpital Specjalistyczny w Legnicy | Legnica | |
| Russian Federation | S.P. Botkin Moscow City Clinical Hospital | Moscow | |
| Russian Federation | Nizhniy Novgorod Region Clinical Hospital | Nizhny Novgorod | |
| Russian Federation | Republican Hospital named by V.A.Baranova | Petrozavodsk | |
| Russian Federation | Ryazan Regional Clinical Hospital | Ryazan | |
| Russian Federation | City Hospital No.15 | Saint-Petersburg | |
| Russian Federation | Saratov State Medical University | Saratov | |
| Russian Federation | Clinical Research Institute of Hematology and Transfusiology | St-Petersburg | |
| Russian Federation | Oncology Dispensary of Komi Republic | Syktyvkar | |
| Spain | Hosp. Univ. Germans Trias I Pujol | Badalona | |
| Spain | Hosp Clinic de Barcelona | Barcelona | |
| Spain | Inst. Cat. Doncologia-H Duran I Reynals | Hospitalet de Llobregat, Barcelona | |
| Spain | Hosp. Univ. de Canarias | La Laguna | |
| Spain | Centro Integral Oncológico Clara Campal | Madrid | |
| Spain | Clinica Univ. de Navarra | Madrid | |
| Spain | Hosp. Gral. Univ. Gregorio Maranon | Madrid | |
| Spain | Hosp. Univ. 12 de Octubre | Madrid | |
| Spain | Hosp. Univ. Ramon Y Cajal | Madrid | |
| Spain | Hosp. Gral. Univ. J.M. Morales Meseguer | Murcia | |
| Spain | Clinica Univ. de Navarra | Pamplona | |
| Spain | Hosp Clinico Univ de Salamanca | Salamanca | |
| Spain | Hosp. Univ. Dr. Peset | Valencia | |
| Ukraine | Communal Nonprofit Enterprise 'Cherkasy Regional Oncology Dispensary Of Cherkasy Regional Council' | Cherkasy | |
| Ukraine | Dnepropetrovsk City Clinical Hospital #4, Regional Hematology Center | Dnepropetrovsk | |
| Ukraine | Kharkov Regional Clinical Oncology Center, Dept. of Hematology | Kharkov | |
| Ukraine | Vinnytsya Regional Clinical Hospital named after M.I.Pirogov | Vinnitsa | |
| United States | University of Michigan Comprehensive Cancer Center | Ann Arbor | Michigan |
| United States | Baylor University Medical Center | Dallas | Texas |
| United States | University of Miami Sylvester Cancer Center | Miami | Florida |
| United States | Icahn School of Medicine at Mount Sinai - The Derald H. Ruttenberg | New York | New York |
| United States | Memorial Sloan Kettering Cancer Center | New York | New York |
| United States | Washington University in St. Louis | Saint Louis | Missouri |
| Lead Sponsor | Collaborator |
|---|---|
| Janssen Research & Development, LLC |
United States, Belgium, China, Denmark, France, Germany, Greece, Korea, Republic of, Poland, Russian Federation, Spain, Ukraine,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Number of Participants with Serious Adverse Events (SAEs) | Number of participants with SAEs will be reported. SAE is any AE that results in: death, persistent or significant disability/incapacity, requires inpatient hospitalization or prolongation of existing hospitalization, is life-threatening experience, is a congenital anomaly/birth defect, and suspects transmission of any infectious agent via a medicinal product. | 3 years 7 months | |
| Primary | Number of Participants with AEs of Special Interest (AESI) | Number of participants with AESI, that is, reactivation of HBV infection, will be reported. | 3 years 7 months | |
| Primary | Number of Participants with Pregnancies or Partner Pregnancies | Number of participants with pregnancies or partner pregnancies will be reported using the appropriate pregnancy notification form. | 3 years 7 months | |
| Primary | Number of Participants with Abnormal Pregnancies as SAE | Number of Participants with Abnormal Pregnancies as SAE will be reported. | 3 years 7 months |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05027594 -
Ph I Study in Adult Patients With Relapsed or Refractory Multiple Myeloma
|
Phase 1 | |
| Completed |
NCT02412878 -
Once-weekly Versus Twice-weekly Carfilzomib in Combination With Dexamethasone in Adults With Relapsed and Refractory Multiple Myeloma
|
Phase 3 | |
| Completed |
NCT01947140 -
Pralatrexate + Romidepsin in Relapsed/Refractory Lymphoid Malignancies
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05971056 -
Providing Cancer Care Closer to Home for Patients With Multiple Myeloma
|
N/A | |
| Recruiting |
NCT05243797 -
Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
|
Phase 3 | |
| Active, not recruiting |
NCT04555551 -
MCARH109 Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of Multiple Myeloma
|
Phase 1 | |
| Recruiting |
NCT05618041 -
The Safety and Efficay Investigation of CAR-T Cell Therapy for Patients With Hematological Malignancies
|
N/A | |
| Active, not recruiting |
NCT03844048 -
An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial
|
Phase 3 | |
| Recruiting |
NCT03412877 -
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
|
Phase 2 | |
| Completed |
NCT02916979 -
Myeloid-Derived Suppressor Cells and Checkpoint Immune Regulators' Expression in Allogeneic SCT Using FluBuATG
|
Phase 1 | |
| Recruiting |
NCT03570983 -
A Trial Comparing Single Agent Melphalan to Carmustine, Etoposide, Cytarabine, and Melphalan (BEAM) as a Preparative Regimen for Patients With Multiple Myeloma Undergoing High Dose Therapy Followed by Autologous Stem Cell Reinfusion
|
Phase 2 | |
| Completed |
NCT03665155 -
First-in- Human Imaging of Multiple Myeloma Using 89Zr-DFO-daratumumab, a CD38-targeting Monoclonal Antibody
|
Phase 1/Phase 2 | |
| Terminated |
NCT03399448 -
NY-ESO-1-redirected CRISPR (TCRendo and PD1) Edited T Cells (NYCE T Cells)
|
Phase 1 | |
| Completed |
NCT02812706 -
Isatuximab Single Agent Study in Japanese Relapsed AND Refractory Multiple Myeloma Patients
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT05024045 -
Study of Oral LOXO-338 in Patients With Advanced Blood Cancers
|
Phase 1 | |
| Active, not recruiting |
NCT03989414 -
A Study to Determine the Recommended Dose and Regimen and to Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Treatments in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) and Newly Diagnosed Multiple Myeloma (NDMM)
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT03792763 -
Denosumab for High Risk SMM and SLiM CRAB Positive, Early Myeloma Patients
|
Phase 2 | |
| Withdrawn |
NCT03608501 -
A Study of Ixazomib, Thalidomide and Dexamethasone in Newly Diagnosed and Treatment-naive Multiple Myeloma (MM) Participants Non-eligible for Autologous Stem-cell Transplantation
|
Phase 2 | |
| Recruiting |
NCT04537442 -
Clinical Study to Evaluate the Safety and Efficacy of IM21 CAR-T Cells in the Treatment of Elderly Patients With Relapsed or Refractory Multiple Myeloma
|
Phase 1 | |
| Completed |
NCT02546167 -
CART-BCMA Cells for Multiple Myeloma
|
Phase 1 |